5-fluorouracil + cisplatin + cyclophosphamide + docetaxel + epirubicin

This is a multi-agent chemotherapy regimen composed of five cytotoxic drugs: 5-fluorouracil, cisplatin, cyclophosphamide, docetaxel, and epirubicin. Each component has a distinct mechanism of action targeting rapidly dividing cancer cells through different pathways: - **5-fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - **Cisplatin** is a platinum-based compound that forms DNA crosslinks and induces apoptosis. - **Cyclophosphamide** is an alkylating agent causing DNA strand breakage. - **Docetaxel** stabilizes microtubules and prevents cell division by inhibiting depolymerization. - **Epirubicin**, an anthracycline antibiotic similar to doxorubicin, intercalates into DNA and inhibits topoisomerase II. This combination would be considered highly intensive and experimental; while combinations of three or four of these agents (such as TPF—docetaxel, cisplatin, fluorouracil—or regimens including cyclophosphamide with anthracyclines) are established in the treatment of various solid tumors (notably breast cancer and head & neck cancers), there are no standard regimens or published studies using all five together. The rationale for combining multiple agents with non-overlapping mechanisms is to maximize tumor cell kill while attempting to avoid complete cross-resistance[4][6]. However, toxicity risk increases substantially with each added drug.